283 related articles for article (PubMed ID: 30073640)
1. Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.
Hatzoglou V; Oh JH; Buck O; Lin X; Lee M; Shukla-Dave A; Young RJ; Peck KK; Vachha B; Holodny AI; Grommes C
J Neurooncol; 2018 Nov; 140(2):351-358. PubMed ID: 30073640
[TBL] [Abstract][Full Text] [Related]
2. New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact.
Blasel S; Vorwerk R; Kiyose M; Mittelbronn M; Brunnberg U; Ackermann H; Voss M; Harter PN; Hattingen E
J Neurol; 2018 Mar; 265(3):647-658. PubMed ID: 29383512
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict chemotherapeutic responses and survival in primary central-nervous-system lymphoma.
Fu F; Sun X; Li Y; Liu Y; Shan Y; Ji N; Wang X; Lu J; Sun S
Eur Radiol; 2021 Apr; 31(4):1863-1871. PubMed ID: 32997181
[TBL] [Abstract][Full Text] [Related]
4. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging.
Xi YB; Kang XW; Wang N; Liu TT; Zhu YQ; Cheng G; Wang K; Li C; Guo F; Yin H
Eur J Radiol; 2019 Mar; 112():59-64. PubMed ID: 30777220
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma.
Lu S; Wang S; Gao Q; Zhou M; Li Y; Cao P; Hong X; Shi H
J Comput Assist Tomogr; 2017; 41(6):898-903. PubMed ID: 28806317
[TBL] [Abstract][Full Text] [Related]
7. Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma.
Kim YS; Choi SH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH
Sci Rep; 2018 Jan; 8(1):456. PubMed ID: 29323247
[TBL] [Abstract][Full Text] [Related]
8. Contrast-Enhanced MRI Texture Parameters as Potential Prognostic Factors for Primary Central Nervous System Lymphoma Patients Receiving High-Dose Methotrexate-Based Chemotherapy.
Chen C; Zhuo H; Wei X; Ma X
Contrast Media Mol Imaging; 2019; 2019():5481491. PubMed ID: 31777472
[TBL] [Abstract][Full Text] [Related]
9. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
[TBL] [Abstract][Full Text] [Related]
10. Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents?
Meling TR; Latysheva A; Da Broi M; Jahr G; Holte H; Beiske K; Emblem KE
Neuroradiology; 2018 Jul; 60(7):703-713. PubMed ID: 29804159
[TBL] [Abstract][Full Text] [Related]
11. Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment.
Zhang Y; Zhang Q; Wang XX; Deng XF; Zhu YZ
Clin Radiol; 2016 Oct; 71(10):1018-1029. PubMed ID: 27341986
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics, Surgical Outcomes, and Prognostic Factors of Intracranial Primary Central Nervous System Lymphoma.
Ouyang T; Wang L; Zhang N; Zhang Z; Xiong Y; Li M; Hong T
World Neurosurg; 2020 Jul; 139():e508-e516. PubMed ID: 32311566
[TBL] [Abstract][Full Text] [Related]
13. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
[TBL] [Abstract][Full Text] [Related]
15. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ
J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843
[TBL] [Abstract][Full Text] [Related]
16. Differentiating between Glioblastoma and Primary CNS Lymphoma Using Combined Whole-tumor Histogram Analysis of the Normalized Cerebral Blood Volume and the Apparent Diffusion Coefficient.
Bao S; Watanabe Y; Takahashi H; Tanaka H; Arisawa A; Matsuo C; Wu R; Fujimoto Y; Tomiyama N
Magn Reson Med Sci; 2019 Jan; 18(1):53-61. PubMed ID: 29848919
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment intratumoral susceptibility signals correlate with response to high-dose methotrexate and progression-free survival in primary central nervous system lymphoma.
Deguchi S; Nakashima K; Muramatsu K; Mitsuya K; Oishi T; Shirata K; Hayashi N; Sugino T; Endo M; Nakasu Y
J Clin Neurosci; 2019 Nov; 69():43-50. PubMed ID: 31427235
[TBL] [Abstract][Full Text] [Related]
18. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.
Ulyte A; Katsaros VK; Liouta E; Stranjalis G; Boskos C; Papanikolaou N; Usinskiene J; Bisdas S
Neuroradiology; 2016 Dec; 58(12):1197-1208. PubMed ID: 27796446
[TBL] [Abstract][Full Text] [Related]
20. Multiparametric imaging-based differentiation of lymphoma and glioblastoma: using T1-perfusion, diffusion, and susceptibility-weighted MRI.
Saini J; Kumar Gupta P; Awasthi A; Pandey CM; Singh A; Patir R; Ahlawat S; Sadashiva N; Mahadevan A; Kumar Gupta R
Clin Radiol; 2018 Nov; 73(11):986.e7-986.e15. PubMed ID: 30197047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
